Stemvax: Quest Management Inc. Signs Letter of Intent to Acquire Immunotherapy Biotech Company Stemvax, Inc.
Quest Management Inc. (OTC:QSMG) announces the signing of a Letter of Intent (the "Agreement") to acquire immunotherapy Biotech company Stemvax, Inc., from Dr. Dwain Morris-Irvin PhD. Upon Closing, Dr. Morris-Irvin will simultaneously become CEO of the newly formed Biotech division of Quest.
Read full article »
StemVax is a biotechnology company that develops and commercializes stem cell-based immunotherapies for the treatment of brain tumor.
Read more